March 26 (Reuters) - OSR Holdings Inc OSRH.O:
VAXIMM AG, AN OSR COMPANY, ANNOUNCES RESULTS FROM PHASE 2A TRIAL OF VXM01 AND AVELUMAB COMBINATION THERAPY IN GLIOBLASTOMA
VAXIMM AG - PHASE 2A TRIAL SHOWS GOOD SAFETY AND TOLERABILITY PROFILE
VAXIMM AG - NO SERIOUS ADVERSE EVENTS ATTRIBUTED TO VXM01
VAXIMM AG- DECREASED TUMOR SIZE OBSERVED IN RESPONDING PATIENTS
Source text: ID:nPn8QQQdYa
Further company coverage: OSRH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.